PubRank

Fehmida Visnegarwala

Author PubWeight™ 29.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005 5.08
2 Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008 2.93
3 Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002 2.75
4 Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care 2005 2.64
5 The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005 2.43
6 Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003 2.33
7 Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009 1.96
8 Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005 1.42
9 Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007 1.25
10 Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002 1.18
11 Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 2003 1.12
12 Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003 1.04
13 The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. AIDS 2010 0.89
14 Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2003 0.88
15 Visceral and subcutaneous adiposity measurements in adults: influence of measurement site. Obesity (Silver Spring) 2007 0.87
16 Effects of rosiglitazone on abnormal lipid kinetics in HIV-associated dyslipidemic lipodystrophy: a stable isotope study. Metabolism 2010 0.79
17 Predictors of HIV positivity among pregnant women presenting for obstetric care in South India - a case-control study. AIDS Care 2011 0.79
18 Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus non-protease inhibitor containing HAART regimens. J Acquir Immune Defic Syndr 2003 0.75
19 Use of bDNA testing in the immunologically nonresponding patient who has a low or undetectable viral load by RT-PCR testing. HIV Clin Trials 2003 0.75
20 Unusual manifestations of disseminated Histoplasmosis in patients responding to antiretroviral therapy. Am J Med 2005 0.75